Associated Papers
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
Shariq OA et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Incidence and distribution of neck node metastases in hereditary vs. sporadic medullary thyroid cancer at basal calcitonin serum levels ≤100 pg/ml: 30-year experience.
Machens A et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2025
RET (C620R) Mutation in a Hirschsprung Disease Family: A Case Report Unveiling Asymptomatic Pheochromocytoma and Unmanifested Medullary Thyroid Carcinoma.
Tanaka Y et al.
Cureus, 2025
RET C611Y Germline Variant in Multiple Endocrine Neoplasia Type 2A in Denmark 1930-2021: A Nationwide Study.
Hansen AW et al.
Cancers, 2025
Genotype-phenotype correlations of germline mutations in exon 10 of the RET proto-oncogene from 14 MEN2A families of Ethnic Han Chinese.
Li F et al.
Plos One, 2025
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Current prospects of hereditary adrenal tumors: towards better clinical management.
Ohmoto A et al.
Hereditary Cancer in Clinical Practice, 2024
Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?
Binter T et al.
Cancers, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX et al.
Frontiers in Endocrinology, 2024
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023
RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report.
Neocleous V et al.
Life (basel, Switzerland), 2023
Sex differences in MEN 2A penetrance and expression according to parental inheritance.
Machens A et al.
European Journal of Endocrinology, 2022
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M et al.
Endocrinology and Metabolism (seoul, Korea), 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
Qi XP et al.
Bmc Cancer, 2021
Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
Giardino E et al.
Molecular and Cellular Endocrinology, 2021
Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD et al.
Oncology, 2021
Genetic testing in endocrine surgery: Opportunities for precision surgery.
Alobuia W et al.
Surgery, 2020
Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.
Larsen LV et al.
Endocrine Connections, 2020
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Elisei R et al.
Genes, 2019
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy.
Giacché M et al.
Human Mutation, 2019
A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency.
Pecce V et al.
Plos Genetics, 2018
Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A et al.
Human Mutation, 2018
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R et al.
Pharmacological Research, 2018
A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC et al.
Archives of Endocrinology and Metabolism, 2018
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK et al.
The Journal of Clinical Endocrinology and Metabolism, 2017
Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS et al.
The Journal of Clinical Endocrinology and Metabolism, 2017
Surgical approaches in hereditary endocrine tumors.
Iacobone M et al.
Updates in Surgery, 2017
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M et al.
Critical Reviews in Clinical Laboratory Sciences, 2016
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA et al.
Thyroid : Official Journal of the American Thyroid Association, 2015
In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.
Heineman TE et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2015
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
Multiple endocrine neoplasia type 2: achievements and current challenges.
Machens A et al.
Clinics (sao Paulo, Brazil), 2012
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Waguespack SG et al.
Nature Reviews. Endocrinology, 2011
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
Frank-Raue K et al.
Human Mutation, 2011
Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.
Schreinemakers JM et al.
World Journal of Surgery, 2010
Uncommon MEN2A phenotype in a patient with a RET protooncogene exon 10, codon 611 mutation.
Igaz P et al.
Clinical Endocrinology, 2009
Familial prevalence and age of RET germline mutations: implications for screening.
Machens A et al.
Clinical Endocrinology, 2008
Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G et al.
Expert Review of Anticancer Therapy, 2007
RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.
Margraf RL et al.
The Journal of Molecular Diagnostics : Jmd, 2007
Masking selected sequence variation by incorporating mismatches into melting analysis probes.
Margraf RL et al.
Human Mutation, 2006
Hereditary hormone excess: genes, molecular pathways, and syndromes.
Marx SJ et al.
Endocrine Reviews, 2005